tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Amedisys (AMED), Humana (HUM) and Teladoc (TDOC)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amedisys (AMEDResearch Report), Humana (HUMResearch Report) and Teladoc (TDOCResearch Report).

Amedisys (AMED)

In a report released today, Brian Tanquilut from Jefferies maintained a Buy rating on Amedisys, with a price target of $200.00. The company’s shares closed last Wednesday at $128.16, close to its 52-week low of $101.61.

According to TipRanks.com, Tanquilut is a 4-star analyst with an average return of 5.9% and a 54.9% success rate. Tanquilut covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Privia Health Group, and Acadia Healthcare.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amedisys with a $154.83 average price target, a 20.5% upside from current levels. In a report issued on July 14, Truist Financial also maintained a Buy rating on the stock with a $150.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Humana (HUM)

Jefferies analyst David Windley maintained a Buy rating on Humana yesterday and set a price target of $560.00. The company’s shares closed last Wednesday at $478.35, close to its 52-week high of $497.47.

According to TipRanks.com, Windley is a top 100 analyst with an average return of 15.4% and a 70.3% success rate. Windley covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Molina Healthcare, and Elevance Health.

Humana has an analyst consensus of Strong Buy, with a price target consensus of $528.64, which is an 8.5% upside from current levels. In a report released today, Oppenheimer also maintained a Buy rating on the stock with a $520.00 price target.

Teladoc (TDOC)

In a report released yesterday, Glen Santangelo from Jefferies reiterated a Hold rating on Teladoc, with a price target of $38.00. The company’s shares closed last Wednesday at $43.24, close to its 52-week low of $27.38.

According to TipRanks.com, Santangelo is a 5-star analyst with an average return of 14.2% and a 62.3% success rate. Santangelo covers the Technology sector, focusing on stocks such as Tabula Rasa HealthCare, Health Catalyst, and GoodRx Holdings.

The word on The Street in general, suggests a Hold analyst consensus rating for Teladoc with a $38.85 average price target, implying a -5.5% downside from current levels. In a report issued on July 20, Barclays also maintained a Hold rating on the stock with a $42.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AMED:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More